Tango Therapeutics, Inc. Tango Therapeutics, Inc.

Tango Therapeutics, Inc.

TNGX

Peringkat dalam Saham #4544
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Harga Saham
$27.18
Terakhir disinkronkan: 2026-07-31
Kapitalisasi Pasar
$3.38B
Perubahan (1 hari)
-1.41%
Perubahan (1 tahun)
202.34%
Negara
US
Perdagangan Tango Therapeutics, Inc. (TNGX)

Kategori

Healthcare
Rasio P/S untuk Tango Therapeutics, Inc. (TNGX)
Rasio P/S per October 2026 TTM: 67.14
Menurut laporan keuangan dan harga saham terbaru dari Tango Therapeutics, Inc., rasio P/S saat ini (TTM) adalah 67.14. Pada akhir 2023, rasio P/S perusahaan adalah 25.63.
Riwayat rasio P/S untuk Tango Therapeutics, Inc. dari 2019 hingga 2026
Rasio P/S pada akhir setiap tahun
Tahun Rasio P/S Mengubah
2026 (TTM) 67.14 737.15%
2024 8.02 -68.70%
2023 25.63 0.08%
2022 25.61 39.62%
2021 18.34 -61.56%
2020 47.71 1,179.46%
2019 3.73 0.00%
Rasio P/S untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/S Perbedaan Rasio P/S Negara
10.02 -85.07%
US
40.55 -39.60%
US
3.96 -94.10%
AU
- -
CH
10.15 -84.89%
NL